MODERN ASPECTS OF PATHOGENETIC TREATMENT WITH ZINC SALTS OF PATIENTS WITH WILSON'S DISEASE IN UKRAINE
The aim – to study the effectiveness of zinc salts in the treatment of patients with neurological forms of Wilson's disease (WD).
Materials and methods. The analysis of the treatment results of 128 patients with hepatocerebral degeneration (71 men and 57 women) in the State Institution “Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine” was carried out. At the time of hospitalization, the age of patients ranged from 5 to 55 years, an average of 27.3 years, and at the time of debut of the disease - from 1 year to 40 years, an average of 21.3 years. 33 patients underwent monotherapy with zinc salts, 63 – combined therapy with small doses of penicillamine and zinc salts, 32 – monotherapy with penicillamine.
Results. Because of the treatment, 67.1 % of patients showed an improvement in neuropsychiatric status: speech improved significantly, tremor of the extremities and the amplitude of hyperkinesis decreased, muscle tone decreased, and cognitive functions improved. According to the international two-level rating scale (UWDRS), the total pathology index decreased by 21 points. Zinc salts are effective and low-toxic and can be the drug of choice in the treatment of patients with hepatocerebral degeneration in the pre-symptomatic stage of the disease, as well as at the stage of maintenance treatment, both as monotherapy and in combination with penicillamine. However, zinc salts and penicillamine are not enough for the treatment and rehabilitation of patients with hepatocerebral degeneration. Therefore, taking into account the clinical picture and the data of additional research methods, it is necessary to conduct courses of symptomatic treatment at least 1-2 times a year.
Conclusions. Thus, it can be noted that zinc salts are very effective and low toxic, and, therefore, can be the drug of choice in the treatment of patients with HCD in the pre-symptomatic stage of the disease, as well as at the stage of maintenance therapy as a single drug, and in combination with penicillamine or other chelate drugs.
Roberts, E. A., Schilsky, M. L. (2008). Diagnosis and treatment of Wilson disease: An update. Hepatology, 47 (6), 2089–2111. doi: http://doi.org/10.1002/hep.22261
Tsivkovskii, R., Eisses, J. F., Kaplan, J. H. et. al. (2002). Functional properties of the copper-transporting ATPase ATP7B (the Wilson’s disease protein) expressed in insect cells. Journal of Biological Chemistry, 277 (2), 976–983. doi: http://doi.org/10.1074/jbc.m109368200
Brewer, G. J., Askari, F., Lorincz, M. T., Carlson, M., Schilsky, M., Kluin, K. J. et. al. (2006). Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Archives of Neurology, 63 (4), 521–527. doi: http://doi.org/10.1001/archneur.63.4.521
Walshe, J. M. (1956). Penicillamine, a new oral therapy for Wilson’s disease. The American Journal of Medicine, 21, 487—495. doi: http://doi.org/10.1016/0002-9343(56)90066-3
Lowette, K. F., Desmet, K., Witters, P., Laleman, W., Verslype, C., Nevens, F. et. al. (2010). Wilsonʼs disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine. European Journal of Gastroenterology & Hepatology, 22 (5), 564–571. doi: http://doi.org/10.1097/meg.0b013e3283353df8
Merle, U., Schaefer, M., Ferenci, P., Stremmel, W. (2007). Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut, 56, 115–120. doi: http://doi.org/10.1136/gut.2005.087262
Czlonkowska, A., Gajda, J., Rodo, M. (2006). Effectsof long-term treatment in Wilson’s disease with Dpenicillamine and zinc sulphate. Journal of Neurology, 243, 269–273. doi: http://doi.org/10.1007/bf00868525
Schouwink, G. (1961). Dehepatocerebrale degeneratie, met een onderzoek naar de koperstofwisseling. University of Amsterdam.
Medici, V., Trevisan, C. P., D’Incj, R., Barollo, M., Zancan, L., Fagiuoli, S. et. al. (2006). Diagnosis and management of Wilson’s disease: results of a single center experience. Journal of Clinical Gastroenterology, 40 (10), 936–941. doi: http://doi.org/10.1097/01.mcg.0000225670.91722.59
Sinha, S., Taly, A. B. (2008). Withdrawal of penicillamine from zinc sulphatepenicillamine maintenance therapy in Wilson’s disease: promising, safe and cheap. Journal of the Neurological Sciences, 264 (1-2), 129–132. doi: http://doi.org/10.1016/j.jns.2007.08.006
Wiggelinkhuizen, M., Tilanus, M. E. C., Bollen, C. W., Houwen, R. H. J. (2009). Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Alimentary Pharmacology & Therapeutics, 29 (9), 947–958. doi: http://doi.org/10.1111/j.1365-2036.2009.03959.x
Linn, F. H. H., Houwen, R. H. J., van Hattum, J., van der Kleij, S., van Erpecum, K. J. (2009). Long-term exclusive zinc monotherapy in symptomatic Wilson disease: Experience in 17 patients. Hepatology, 50 (5), 1442–1452. doi: http://doi.org/10.1002/hep.23182
Chang, H., Xu, A., Chen, Z., Zhang, Y., Tian, F., Li, T. (2013). Long-term effects of a combination of D-penicillamine and zinc salts in the treatment of Wilson’s disease in children. Experimental and Therapeutic Medicine, 5 (4), 1129–1132. doi: http://doi.org/10.3892/etm.2013.971
Weiss, K. H., Gotthardt, D. N., Klemm, D., Merle, U., Ferenci–Foerster, D., Schaefer, M. et. al. (2011). Zinc Monotherapy Is Not as Effective as Chelating Agents in Treatment of Wilson Disease. Gastroenterology, 140 (4), 1189–1198. doi: http://doi.org/10.1053/j.gastro.2010.12.034
Hoogenraad, T. U. (2006). Paradigm shift in treatment of Wilson’s disease: zinc therapy now treatment of choice. Brain and Development, 28, 141–146. doi: http://doi.org/10.1016/j.braindev.2005.08.008
Aggarwal, A., Aggarwal, N., Nagral, A., Jankharia, G., Bhatt, M. (2009). A Novel Global Assessment Scale for Wilson’s disease (GAS for WD). Movement Disorders, 24, 509–518. doi: http://doi.org/10.1002/mds.22231
Shimizu, N., Fujiwara, J., Ohnishi, S., Sato, M., Kodama, H., Kohsaka, T. et. al. (2010). Effects of long-term zinc treatment in Japanese patients with Wilson disease: efficacy, stability, and copper metabolism. Translational Research, 156 (6), 350–357. doi: http://doi.org/10.1016/j.trsl.2010.08.007
Stremmel, W. (1991). Wilson Disease: Clinical Presentation, Treatment, and Survival. Annals of Internal Medicine, 115 (9), 720–726. doi: http://doi.org/10.7326/0003-4819-115-9-720
Rakhimova, O. Iu. (2005). Varianty porazheniia pochek pri bolezni Vilsona – Konovalova. Moscow.
Copyright (c) 2019 Ivan Voloshyn-Gaponov
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.